Promising new combo tackles rare leukemia complication
NCT ID NCT04679012
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the drug polatuzumab vedotin to standard chemotherapy can improve remission rates in people with Richter's transformation, an aggressive lymphoma that can develop from chronic lymphocytic leukemia (CLL). About 20 adults with confirmed Richter's transformation will receive up to six cycles of the combination therapy. Researchers will track how many achieve complete remission and monitor side effects over about two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Polatuzumab vedotin (Polivy) combined with rituximab, etoposide, prednisone, cyclophosphamide, and hydroxydaunorubicin
What this could lead to
If successful, this could offer a more effective treatment option for Richter's transformation, a rare and aggressive complication of chronic lymphocytic leukemia.
What could go wrong
This is a small, early-phase (phase 2) study with only 20 participants, so results may not apply broadly. The combination chemotherapy has significant side effects, and the drug may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact
-
Mount Sinai- Icahn School of Medicine
RECRUITINGNew York, New York, 10029, United States
Contact
Contact
-
Ohio state University
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••